

The Health Alliance adds unique cancer testing company

The Health Alliance continues to disrupt health care by adding new lung cancer testing company.

RALEIGH, NC, UNITED STATES, April 3, 2024
/EINPresswire.com/ -- The Health Alliance Expands Cancer
Testing Capabilities with New Liquid Biopsy Company

The Health Alliance, a leading healthcare organization, is pleased to announce the addition of a new liquid biopsy cancer testing company to its network. This proprietary test is the first of its kind in the country and is designed to aid in the early detection of Lung cancer. The Health Alliance is excited to welcome this new member to its team, as it will greatly enhance the organization's ability to diagnose and treat lung cancer.

The new liquid biopsy test utilizes advanced technology to detect cancer cells in a patient's blood or other bodily fluids. This non-invasive method allows for the detection of cancer at an early stage, when it is most treatable. The test is also able to identify specific genetic mutations, providing valuable

A National Network
WITH LIMITLESS POSSIBILITIES

• Access and opportunities with
enterprise customers
• Full test menu and service offerings
• Easier talent acquisition with incredible
opportunity for professional growth
and upward mobility
• National managed care & payer
relations strategy and execution

Benefits of the health alliance

information for personalized treatment plans. This breakthrough technology has the potential to greatly improve patient outcomes and reduce the need for invasive procedures.

The Health Alliance is committed to providing the highest quality of care to its patients, and the addition of this new liquid biopsy company further solidifies this commitment. The company specializes in <u>research</u>, pathology, biobanking, and clinical <u>lab testing</u>, making it a valuable asset to the Health Alliance's cancer treatment capabilities. With this new addition, oncologists will have access to cutting-edge technology and resources to aid in the diagnosis and treatment of lung cancer.

The Health Alliance is proud to be at the forefront of advancements in cancer testing and treatment. The addition of this new liquid biopsy company is a testament to the organization's dedication to providing the best possible care for its patients. The Health Alliance looks forward

to the positive impact this new technology will have on the early detection and treatment of lung cancer.

Ryan Angel
The Health Alliance
email us here
Visit us on social media:
Other

This press release can be viewed online at: https://www.einpresswire.com/article/700321781

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.